CAMBRIDGE, Mass.–(BUSINESS WIRE)–QurAlis Corporation (“QurAlis”), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for QRL-201 for the treatment of amyotrophic lateral sclerosis (ALS). The clearance enables QurAlis to advance the planned pivotal CONQUR clinical trial in the U.S. The company also announced final data from the dose-range finding (DRF) phase of its Proof-of-Concept Phase 1/2 ANQUR clinical trial of QRL-20